🇺🇸▼
A sudden change in government rules by the Food and Drug Administration (FDA) regarding Moderna's new flu vaccine has revealed major dangers for companies that invest in new medicines. In late 2023, the FDA initially indicated it would not look at an application to approve Moderna's mRNA flu shot. This quick decision caused strong criticism from experts in public health. They argued that rejecting such a potentially important medical tool was a serious error. However, only one week later, the FDA changed its mind. The agency said it would review the vaccine. This review might allow approval in time for the upcoming flu season. After this news, the value of Moderna's stock went up. The company recovered most of the money it lost after the initial rejection.
Before the FDA officially rejected the application, Moderna and other large drug companies had already started to cut spending on their vaccine projects. This drop in investment came from growing fear about the unpredictable and strict nature of the FDA's approval process. As a law professor who studies vaccine policy, I believe the FDA's sudden change will not fix the deep worry among investors and company leaders. The instability shows that the hurdles for getting approval could become even harder to clear in the future. This situation discourages the new ideas needed to fight seasonal diseases. When companies cannot know if their hard work and billions of dollars will lead to approval, they hesitate to take the necessary risks.
Now that the FDA has agreed to review the application, the rules are different depending on the age of the patient. For people between the ages of 50 and 64, the FDA stated it will evaluate the vaccine using the standard review path. This is the same rigorous process used to check the vast majority of new drugs and biological products. Under this standard, the agency requires detailed data proving the drug is safe and effective. These tests must show that the vaccine works in thousands of people and does not cause dangerous side effects.
In its original decision to decline the application, the FDA claimed that Moderna had not done an adequate and well-controlled study. The agency argued that the company failed to compare patients receiving its vaccine against those receiving what the FDA considered the best available standard of care. Basically, the agency insisted on a direct comparison with the most effective existing vaccines on the market. The agency's decision to review the vaccine now effectively reverses this position. It is important to note that the initial refusal was not based on a specific, unchangeable law. Instead, it was based on an interpretation that the agency has now changed.
For people aged 65 and older, the FDA indicated it will review the vaccine through a long-standing program known as accelerated approval. This pathway is designed to speed up the review of drugs that treat serious conditions and fill a medical need that is not currently met. It is typically reserved for treatments that show great promise where waiting for complete long-term data could cost lives. Under the accelerated approval framework, federal law allows the FDA to consider different types of data than those required under standard approval. Instead of demanding final clinical results that take years to compile, a company may submit results that use a proxy measurement. This proxy serves as an indicator that the drug is likely to achieve its intended clinical goal, even if the final outcome is not yet fully confirmed.
If the FDA approves Moderna's vaccine for this older age group under this expedited process, the company will be legally required to conduct additional studies afterward. These studies must confirm the vaccine's effectiveness and safety in the real world. What makes the FDA's recent move particularly unusual is the timing of this suggestion. Typically, the agency advises manufacturers to use the accelerated approval pathway much earlier in the drug development process. They often suggest this before the final application is submitted. Invoking this pathway only after a standard application was initially rejected is a rare and potentially confusing precedent. This inconsistency makes it difficult for companies to plan their research strategies effectively.